Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 multicenter randomized blinded trial of adamgammadex sodium versus Bridion for reversal of rocuronium-induced neuromuscular blockade
ChiCTR2000039525Phase 3Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neuromuscular block (NMB) comparing Adamgammadex Sodium 4 mg/kg with Bridion 2 mg/kg (2 arms). Primary endpoint: Time from administration to TOF ratio recovery to 0.9. Started Dec 2020; status: recruiting.
02
Drugs
adamgammadexSugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on ChiCTR2000039525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039525.